GlassScriptPhysician profile
Susan M Ogden
NPI 1790231470
$8,243.73
in general payments reported to CMS, 2019-2025
52 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,558 · 2022: $3,332 · 2023: $527 · 2024: $716 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,118.24 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $843.87 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $775.27 | 2021-2023 | Farxiga, Fasenra |
| Amgen INC. | $704.38 | 2021-2024 | Repatha, Otezla |
| Lilly USA, LLC | $392.48 | 2021-2023 | Mounjaro |
| Avanir Pharmaceuticals, INC. | $374.70 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $325.12 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $262.68 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.10 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $247.28 | 2021-2023 | Dificid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $242.38 | 2022-2023 | |
| Glaxosmithkline, LLC. | $225.22 | 2021-2023 | Shingrix, Arexvy |
| Paratek Pharmaceuticals, INC. | $220.89 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $209.60 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $140.00 | 2024 | Austedo Xr |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Ogden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.